Targets › CSF1R
24 programs from 22 companies in 72 trials: 31 Phase 1, 29 Phase 2, 12 Phase 3; Oncology, Respiratory, Other; next expected readout Nov 2026.
Tyrosine-protein kinase that acts as a cell-surface receptor for CSF1 and IL34 and plays an essential role in the regulation of survival, proliferation and differentiation of hematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes. Promotes the release of pro-inflammatory chemokines in response to IL34 and CSF1, and thereby plays an important role in innate immunity and in…. (UniProt, P07333)
Open in Phaseline: the race on CSF1R, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Gossamer Bio USA | Seralutinib Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor; Macrophage colony stimulating factor receptor inhibitor | KIT, PDGFRB, PDGFRA, CSF1R | Phase 3 | Pulmonary Arterial Hypertension | Dec 2026 |
| Deciphera Pharmaceuticals | Vimseltinib (DCC-3014) KIT/PDGFRA/CSF1R inhibitor | CSF1R, KIT, PDGFRA | Phase 3 | Tenosynovial Giant Cell Tumor; Chronic Graft-Versus-Host Disease (cGVHD); Healthy Participants; Healthy Male Participants … | Dec 2026 |
| Xynomic Pharmaceuticals | Pazopanib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase LCK inhibitor | CSF1R, KIT, LCK, FGFR3, FGFR1 | Phase 3 | Renal Cell Carcinoma; Leiomyosarcoma or Carcinosarcoma; Soft Tissue Sarcoma; Rhabdomyosarcoma, Recurrent, Refractory … | Dec 2026 |
| Incyte | Axatilimab Macrophage colony stimulating factor receptor inhibitor | CSF1R | Phase 3 | Chronic Graft-versus-host-disease; TNBC - Triple-Negative Breast Cancer; Hodgkin Lymphoma; Chronic Graft Versus Host Disease … | Jan 2027 |
| National Cancer Institute (NCI) | Pazopanib Hydrochloride Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase LCK inhibitor | CSF1R, KIT, LCK, FGFR3, FGFR1 | Phase 3 | Clear Cell Renal Cell Carcinoma; Foregut Neuroendocrine Tumor; Solid Neoplasm | Feb 2027 |
| Daiichi Sankyo | Pexidartinib Macrophage colony stimulating factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Stem cell growth factor receptor inhibitor | CSF1R, FLT3, KIT | Phase 3 | Tenosynovial Giant Cell Tumor; Neurofibroma, Plexiform | Mar 2027 |
| Daiichi Sankyo | Quizartinib Macrophage colony stimulating factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Stem cell growth factor receptor inhibitor | CSF1R, FLT3, KIT, PDGFRB, PDGFRA | Phase 3 | Leukemia; Acute Myeloid Leukemia; Hepatic Impairment; Acute Myeloid Leukemia, Adult … | May 2027 |
| Abbisko Therapeutics | Pimicotinib capsule CSF1R inhibitor | CSF1R | Phase 3 | Tenosynovial Giant Cell Tumor; Healthy Subjects | Jun 2028 |
| SynOx Therapeutics | Emactuzumab Macrophage colony stimulating factor receptor inhibitor | CSF1R | Phase 3 | TGCT | Sep 2030 |
| Syndax Pharmaceuticals | Axatilimab Macrophage colony stimulating factor receptor inhibitor | CSF1R | Phase 2 | Idiopathic Pulmonary Fibrosis; Chronic Graft-versus-host-disease | Nov 2026 |
| M.D. Anderson Cancer Center | Sunitinib Malate Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Renal Cell Carcinoma; Malignant Neoplasms of Urinary Tract; Prostate Cancer | Dec 2026 |
| National Cancer Institute (NCI) | Sunitinib Malate Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Advanced Lymphoma; Metastatic Pancreatic Neuroendocrine Tumor | Dec 2026 |
| Canadian Cancer Trials Group | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Advanced Rare Tumours | Dec 2026 |
| University of Miami | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Gastrointestinal Stromal Tumors | Dec 2026 |
| Sarcoma Alliance for Research through Collaboration | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Gastrointestinal Stromal Tumors | Jun 2027 |
| American Society of Clinical Oncology | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Lymphoma, Non-Hodgkin | Dec 2027 |
| Bai-Rong Xia | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Ovary Cancer | Dec 2027 |
| Memorial Sloan Kettering Cancer Center | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Osteosarcoma | Mar 2028 |
| Merck KGaA | Pimicotinib CSF1R tyrosine kinase inhibitor | CSF1R | Phase 2 | Tenosynovial Giant Cell Tumor | Aug 2028 |
| Turning Point Therapeutics | elzovantinib (TPX-0022) MET/CSF1R/SRC inhibitor | MET, CSF1R, SRC | Phase 1 | Advanced Solid Tumor | Mar 2027 |
| State University of New York at Buffalo | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 1 | Carcinoma, Renal Cell | Jul 2027 |
| University of Colorado, Denver | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 1 | Osteosarcoma | Aug 2027 |
| Qurient | Adrixetinib (Q702) Axl/Mer/CSF1R selective tyrosine kinase inhibitor | AXL, MER, CSF1R | Phase 1 | Esophageal Cancer; Chronic Graft-Versus-Host Disease | Dec 2027 |
| Rabin Medical Center | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 1 | Solid Tumors Refractory to Standard Therapy | Jan 2028 |
Chronic Graft-versus-host-disease (6) Acute Myeloid Leukemia (6) Tenosynovial Giant Cell Tumor (4) Renal Cell Carcinoma (3) Chronic Graft Versus Host Disease (2) Pulmonary Arterial Hypertension (2) Osteosarcoma (2) Gastrointestinal Stromal Tumors (2) Leiomyosarcoma or Carcinosarcoma (2) Idiopathic Pulmonary Fibrosis (1) Advanced Rare Tumours (1) TGCT (1)
small molecule (18), antibody (3), mixed (3)
Daiichi Sankyo (2) National Cancer Institute (NCI) (2) Syndax Pharmaceuticals (1) Canadian Cancer Trials Group (1) SynOx Therapeutics (1) Incyte (1) Turning Point Therapeutics (1) Deciphera Pharmaceuticals (1) Merck KGaA (1) Gossamer Bio USA (1) Memorial Sloan Kettering Cancer Center (1) University of Colorado, Denver (1) Sarcoma Alliance for Research through Collaboration (1) Abbisko Therapeutics (1) State University of New York at Buffalo (1) Qurient (1) American Society of Clinical Oncology (1) University of Miami (1) Bai-Rong Xia (1) M.D. Anderson Cancer Center (1)
KIT (17) PDGFRA (14) FLT3 (13) PDGFRB (13) LCK (2) FGFR3 (2) FGFR1 (2) MET (1) SRC (1) AXL (1) MER (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.